TY - JOUR
T1 - Personal and professional use of menopausal hormone therapy among gynecologists
T2 - A multinational study (REDLINC VII)
AU - Danckers, Luis
AU - Blümel, Juan E.
AU - Witis, Silvina
AU - Vallejo, Mariá S.
AU - Tserotas, Konstantino
AU - Sánchez, Hugo
AU - Salinas, Carlos
AU - Saavedra, Javier
AU - Rojas, José A.
AU - Onatra, William
AU - Ojeda, Eliana
AU - Mostajo, Desireé
AU - Morera, Flory
AU - Monterrosa, Alvaro
AU - Montanõ, Armando
AU - Meruvia, Nelva
AU - Martino, Mabel
AU - Martínez, Jaime
AU - Lima, Selva
AU - González, Erik
AU - Gómez, Gustavo
AU - Espinoza, Mariá T.
AU - Castillo, Olivia
AU - Campostrini, Blanca
AU - Calle, Andrés
AU - Broutin, Gerardo
AU - Bencosme, Ascanio
AU - Arteaga, Eugenio
AU - Ayala, Félix
AU - Chedraui, Peter
N1 - Publisher Copyright:
© 2016 Elsevier Ireland Ltd. All rights reserved.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Background Previously, the REDLINC VI study showed that the main reason for the low use of menopausal hormone therapy (MHT) was its low rate of prescription by doctors. Objective To determine the use of MHT and perceived related risks among gynecologists. Methods A self-administered and anonymous questionnaire was delivered to certified gynecologists in 11 Latin American countries. Results A total of 2154 gynecologists were contacted, of whom 85.3% responded to the survey (n = 1837). Mean age was 48.1 ± 11.4 years; 55.5% were male, 20.3% were faculty members and 85% had a partner. Overall, 85.4% of gynecologists responded that they would use MHT if they had menopausal symptoms (81.8% in the case of female gynecologists) or prescribe it to their partner (88.2% in the case of male gynecologists; p < 0.001). Perceived risk related to MHT use (on a scale from 0 to 10) was higher among female than among male gynecologists (4.06 ± 2.09 vs. 3.83 ± 2.11, p < 0.02). The top two perceived reported risks were thromboembolism (women 33.6% vs. men 41.4%, p < 0.009) and breast cancer (women 38.5% vs. men 33.9%, p < 0.03). Overall, gynecologists reported prescribing MHT to 48.9% of their symptomatic patients (women 47.3% vs. men 50.2%, p < 0.03) and 86.8% currently prescribed non-hormonal remedies and 83.8% alternative therapies for the management of the menopause. Gynecologists who were older and academic professionals prescribed MHT more often. Conclusion Although this Latin American survey showed that gynecologists are mostly supporters of MHT use (for themselves or their partners), this is not necessarily reflected in their clinical practice.
AB - Background Previously, the REDLINC VI study showed that the main reason for the low use of menopausal hormone therapy (MHT) was its low rate of prescription by doctors. Objective To determine the use of MHT and perceived related risks among gynecologists. Methods A self-administered and anonymous questionnaire was delivered to certified gynecologists in 11 Latin American countries. Results A total of 2154 gynecologists were contacted, of whom 85.3% responded to the survey (n = 1837). Mean age was 48.1 ± 11.4 years; 55.5% were male, 20.3% were faculty members and 85% had a partner. Overall, 85.4% of gynecologists responded that they would use MHT if they had menopausal symptoms (81.8% in the case of female gynecologists) or prescribe it to their partner (88.2% in the case of male gynecologists; p < 0.001). Perceived risk related to MHT use (on a scale from 0 to 10) was higher among female than among male gynecologists (4.06 ± 2.09 vs. 3.83 ± 2.11, p < 0.02). The top two perceived reported risks were thromboembolism (women 33.6% vs. men 41.4%, p < 0.009) and breast cancer (women 38.5% vs. men 33.9%, p < 0.03). Overall, gynecologists reported prescribing MHT to 48.9% of their symptomatic patients (women 47.3% vs. men 50.2%, p < 0.03) and 86.8% currently prescribed non-hormonal remedies and 83.8% alternative therapies for the management of the menopause. Gynecologists who were older and academic professionals prescribed MHT more often. Conclusion Although this Latin American survey showed that gynecologists are mostly supporters of MHT use (for themselves or their partners), this is not necessarily reflected in their clinical practice.
KW - Gynecologists
KW - Menopausal hormone therapy
KW - Personal use
KW - Prescribing behavior
KW - Professionals
UR - http://www.scopus.com/inward/record.url?scp=84960146031&partnerID=8YFLogxK
U2 - 10.1016/j.maturitas.2016.02.015
DO - 10.1016/j.maturitas.2016.02.015
M3 - Artículo
C2 - 27013290
AN - SCOPUS:84960146031
SN - 0378-5122
VL - 87
SP - 67
EP - 71
JO - Maturitas
JF - Maturitas
ER -